Selection from HEOR Bibliography
| Search criteria | ||||
| Guidelines |
||||
| A review of the sampling methodology used in studies evaluating the effectiveness of risk minimisation measures in Europe. | ||||
| Jouaville LS, Paul T, Almas MF | ||||
| IQVIA | ||||
| Pharmacoepidemiol Drug Saf. 2021 Sep;30(9):1143-1152. doi: 10.1002/pds.5301. |
||||
| , Article | ||||
| , Europe | ||||
| Abstract: https://onlinelibrary.wiley.com/doi/full/10.1002/pds.5301 | ||||
| Condition | Year | Language | Analysis type | |
| , Guidelines, Methodology, Risk Management & REMS | 2021 | English | , Literature Review | |
| Real-world evidence to support regulatory decision making: New or expanded medical product indications | ||||
| Franklin JM, Liaw KL, Iyasu S, Critchlow CW, Dreyer NA. | ||||
| 1Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA. 2Center for Observational and Real-world Evidence, Merck & Co., Inc, Kenilworth, New Jersey, USA. 3Research & Development Strategy and Operations, Amgen, Thousand Oaks, California, USA. 4Real World Solutions, IQVIA, Cambridge, Massachusetts, USA. | ||||
| Pharmacoepidemiol Drug Saf . 2021 Jun;30(6):685-693. doi: 10.1002/pds.5222. Epub 2021 Mar 18. |
||||
| , Article | ||||
| , USA | ||||
| Abstract: https://pubmed.ncbi.nlm.nih.gov/33675248/ | ||||
| Condition | Year | Language | Analysis type | |
| , Guidelines, Regulatory | 2021 | English | , Real World Data, Real World Evidence | |
| Replication of randomized clinical trial results using real-world data: paving the way for effectiveness decisions | ||||
| Kristin M Sheffield , Nancy A Dreyer , James F Murray, Douglas E Faries & Megan N Klopchin | ||||
| 1Global Patient Outcomes & Real World Evidence, Eli Lilly & Company, Indianapolis, IN 46225, USA 2IQVIA Real-World & Analytic Solutions, Cambridge, MA 02139, USA 3Real World Analytics, Eli Lilly & Company, Indianapolis, IN 46225, USA | ||||
| Published Online:11 Sep 2020https://doi.org/10.2217/cer-2020-0161 |
||||
| , Article | ||||
| , USA | ||||
| Abstract: https://www.futuremedicine.com/doi/10.2217/cer-2020-0161 | ||||
| Condition | Year | Language | Analysis type | |
| , Drug safety, Drug Utlization Study, Guidelines, Methodology, Public Health | 2020 | English | , Methodology, Observational study, Population Based Study | |
| Methods for external control groups for single arm trials or long-term uncontrolled extensions to randomized clinical trials | ||||
| John D Seeger 1, Kourtney J Davis 2, Michelle R Iannacone 3, Wei Zhou 4, Nancy Dreyer 5, Almut G Winterstein 6, Nancy Santanello 7, Barry Gertz 8, Jesse A Berlin 2 | ||||
| 1Life Sciences Epidemiology, Optum, Boston, Massachusetts, USA. 2Global Epidemiology, Johnson & Johnson, Titusville, New Jersey, USA. 3Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA. 4Pharmacoepidemiology, Merck & Co., Inc., Kenilworth, New Jersey, USA. 5Real-World Solutions, IQVIA, Cambridge, Massachusetts, USA. 6University of Florida, Gainesville, Florida, USA. 7Nancy Santanello Research Consultant, Philadelphia, Pennsylvania, USA. 8Blackstone, Cambridge, Massachusetts, USA. | ||||
| PMID: 32964514 PMCID: PMC7756307 DOI: 10.1002/pds.5141 Published online 2020 Oct 4. doi: 10.1002/pds.5141 |
||||
| , Article | ||||
| , USA | ||||
| Abstract: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7756307/ | ||||
| Condition | Year | Language | Analysis type | |
| , Guidelines | 2020 | English | , Epidemiological study, Real World Data, Real World Evidence | |
| Dose increase beyond labelled dose of biologics is associated with incremental pharmacy costs: results from a real-world study in the UK | ||||
| Anthony Bewley 1, Cristiana Miglio 2, Haijun Tian 3, Isabelle Gilloteau 4, Joannah Whitehead 5, Ruben Hermans 2 | ||||
| 1a Whipps Cross University Hospital , London , UK. 2b IQVIA , London , UK. 3c Novartis Pharmaceuticals Corporation , East Hanover , NJ , USA. 4d Novartis Pharma AG , Novartis Campus , Basel , Switzerland. 5e Novartis UK Pharmaceuticals Ltd , Frimley, Camberley , UK. | ||||
| J Dermatolog Treat . 2019 Jun;30(4):376-382. doi: 10.1080/09546634.2018.1524820. Epub 2018 Nov 19. |
||||
| , Article | ||||
| , UK | ||||
| Abstract: https://pubmed.ncbi.nlm.nih.gov/30256686/ | ||||
| Condition | Year | Language | Analysis type | |
| , Dermatology, Guidelines, Health status & patient reported outcomes, Infectious disease, Infectious disease | 2019 | English | , Burden of illness, Clinical setting: Primary care, direct-to-patient research, Observational study | |
| Dose increase beyond labelled dose of biologics is associated with incremental pharmacy costs: results from a real-world study in the UK | ||||
| Anthony Bewley 1, Cristiana Miglio 2, Haijun Tian 3, Isabelle Gilloteau 4, Joannah Whitehead 5, Ruben Hermans 2 | ||||
| 1a Whipps Cross University Hospital , London , UK. 2b IQVIA , London , UK. 3c Novartis Pharmaceuticals Corporation , East Hanover , NJ , USA. 4d Novartis Pharma AG , Novartis Campus , Basel , Switzerland. 5e Novartis UK Pharmaceuticals Ltd , Frimley, Camberley , UK. | ||||
| PMID: 30256686 DOI: 10.1080/09546634.2018.1524820 |
||||
| , Article | ||||
| , UK | ||||
| Abstract: https://pubmed.ncbi.nlm.nih.gov/30256686/ | ||||
| Condition | Year | Language | Analysis type | |
| , Drug safety, Drug Utlization Study, Guidelines, Health status & patient reported outcomes | 2019 | English | , direct-to-patient research, Methodology, Survey research | |
| Guidelines in Germany Early Benefit Assessment - Which Guidelines are Considered by Federal Joint Committee for Determining the Appropriate Comparator? | ||||
| Scheler E, Stratil AS, Roxlau T, Bonduelle D | ||||
| IQVIA Commercial GmbH & Co. OHG, Munich, Germany | ||||
| , Abstract, Poster | ||||
| , Germany | ||||
| Condition | Year | Language | Analysis type | |
| , Guidelines, Health policy | 2018 | German | , Review | |
| Cost and treatment of asthma and COPD in the real practice: a regional segmentation | ||||
| Sernissi F1, Rova A1, Mantuano M1, Urbinati D1 | ||||
| QuintilesIMS, Milan, Italy | ||||
| ISPOR 20th Annual European Congress, 4-8 November 2017, Glasgow, Scotland |
||||
| , Poster | ||||
| , Italy | ||||
| Condition | Year | Language | Analysis type | |
| , Guidelines, Respiratory disease | 2017 | English | , Database Study, Literature Review | |
| Comparison of biosimilar guideline and real consumption among Italian regions. | ||||
| Tettamanti A1, Tucci C1, Urbinati D1. | ||||
| 1 IMS Health, Milan, Italy. | ||||
| ISPOR 19th Annual European Congress, 2016, 29 October-2 November, Vienna, Austria. |
||||
| , Poster | ||||
| , Italy | ||||
| Condition | Year | Language | Analysis type | |
| , Guidelines, Health policy | 2016 | English | , Review | |
| The impact of regional legislative measures on the prescription of off-patent medicines. | ||||
| Tettamanti A1, Tucci C1, Urbinati D1. | ||||
| IMS Health, Milan, Italy | ||||
| ISPOR 19th Annual European Congress, 2016, 29 October-2 November, Vienna, Austria. |
||||
| , Poster | ||||
| , Italy | ||||
| Condition | Year | Language | Analysis type | |
| , Guidelines, Health policy | 2016 | English | , Review | |
| Discrepancy between guidelines for stroke prevention in atrial fibrillation and practice patterns in primary care. The nationwide French AFIGP survey | ||||
| Sabouret P1, Bricard M2, Hermann MA2, Cotté FE2, Deret-Bixio L2, Rushton-Smith S3. | ||||
| Heart Institute, Department of Cardiology, Pitié-Salpétrière Hospital, Pierre-and-Marie-Curie University, 75013 Paris, France. Electronic address: pierre.sabouret@psl.aphp.fr. 2Bristol-Myers Squibb, 92500 Rueil-Malmaison, France. 3Thrombosis Research Institute, SW3 6LR London, UK. | ||||
| Arch Cardiovasc Dis. 2015 Nov;108(11):544-53. doi: 10.1016/j.acvd.2015.05.005. Epub 2015 Jun 22. |
||||
| , Article | ||||
| , France | ||||
| Condition | Year | Language | Analysis type | |
| , Cardiovascular disease, Guidelines, Public Health | 2015 | English | , Retrospective database analysis | |
| Use of ADH antagonists results in lower hospital resource usage: a retrospective cohort study | ||||
| Paul Grant 1 , Clare Jamookeeah 2 , Penny Dhanjal 2 & Gethin Griffith 2 | ||||
| 1Royal Sussex County Hospital, Brighton, UK; 2Otsuka Pharmaceuticals (UK) Ltd, Wexham, UK. | ||||
| Endocrine Abstracts (2015) 38 P20 | DOI: 10.1530/endoabs.38.P20 |
||||
| , Abstract | ||||
| , UK | ||||
| Abstract: https://www.endocrine-abstracts.org/ea/0038/ea0038p20 | ||||
| Condition | Year | Language | Analysis type | |
| , Guidelines, Hematology, Methodology | 2015 | English | , Burden of illness, direct to patient research, Retrospective cohort analysis, Review | |